Evidence map›Paper›PMID 36638793›Full record

ArticleCell2023

An E3 ligase network engages GCN1 to promote the degradation of translation factors on stalled ribosomes.

Keely Oltion, Jordan D Carelli, Tangpo Yang, Stephanie K See, Hao-Yuan Wang, Martin Kampmann, Jack Taunton

Open access · greenAbstract read
In one paragraph

Article in Cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 74 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Ribosome-associated quality control and related mechanisms.Nature structural & molecular biology · 2026
    Review
  12. Integrated phenotypic screening and chemical proteomics identifies ETF1 ligands that modulate viral translation and replication.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  13. Quality control and signaling pathways at stalled ribosomes.Experimental & molecular medicine · 2026
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Keely OltionChemistry and Chemical Biology Graduate Program, University of California, San Francisco, San Francisco, CA 94158, USA.
Jordan D CarelliChemistry and Chemical Biology Graduate Program, University of California, San Francisco, San Francisco, CA 94158, USA.
Tangpo YangDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA.
Stephanie K SeeChemistry and Chemical Biology Graduate Program, University of California, San Francisco, San Francisco, CA 94158, USA.
Hao-Yuan WangDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA.
Martin KampmannInstitute for Neurodegenerative Diseases, Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94158, USA; Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.
Jack TauntonDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address: jack.taunton@ucsf.edu.
University of California, San Francisco · US

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kate Taylor Shumate · 1999 to 2026
$209.7M
Research Training in Chemistry and Chemical BiologyT32GM145460 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jason E Gestwicki · 2022 to 2026
$3.1M
Rewiring of the human protein homeostasis network in normal and disease contextsDP2GM119139 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KAMPMANN, MARTIN · 2015 to 2015
$2.3M
NCI NIH HHS P30 CA082103NIGMS NIH HHS DP2 GM119139NIGMS NIH HHS T32 GM145460
6 · The paper itself

Abstract

Ribosomes frequently stall during mRNA translation, resulting in the context-dependent activation of quality control pathways to maintain proteostasis. However, surveillance mechanisms that specifically respond to stalled ribosomes with an occluded A site have not been identified. We discovered that the elongation factor-1α (eEF1A) inhibitor, ternatin-4, triggers the ubiquitination and degradation of eEF1A on stalled ribosomes. Using a chemical genetic approach, we unveiled a signaling network comprising two E3 ligases, RNF14 and RNF25, which are required for eEF1A degradation. Quantitative proteomics revealed the RNF14 and RNF25-dependent ubiquitination of eEF1A and a discrete set of ribosomal proteins. The ribosome collision sensor GCN1 plays an essential role by engaging RNF14, which directly ubiquitinates eEF1A. The site-specific, RNF25-dependent ubiquitination of the ribosomal protein RPS27A/eS31 provides a second essential signaling input. Our findings illuminate a ubiquitin signaling network that monitors the ribosomal A site and promotes the degradation of stalled translation factors, including eEF1A and the termination factor eRF1.

Indexed as

RNA-Binding ProteinsTrans-ActivatorsCarrier ProteinsHEK293 CellsHeLa CellsHumansPeptide Elongation Factor 1Peptide Elongation FactorsProtein BiosynthesisRibosomal ProteinsRibosomesUbiquitinationUbiquitin-Protein LigasesCarrier ProteinsEEF1A1 protein, humanGCN1 protein, humanPeptide Elongation Factor 1Peptide Elongation FactorsRibosomal ProteinsRNA-Binding ProteinsTrans-ActivatorsUbiquitin-Protein LigasesCRISPRi screendiGly proteomicsE3 ligaseK6-linked ubiquitinnatural productprotein synthesisribosomal ubiquitinationribosome quality controlRWD domaintranslation factor

Identifiers

PMID36638793
PMCPMC9994462
OpenAlexW4315784839

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.